Impact of Insulin Degludec in Type 2 Diabetes: Real-World Data on Effectiveness and Safety

[11] Rasmussen S(2006)Dispelling myths and removing barriers about insulin in type 2 diabetes Diabetes Educ 32 9S-373

[12] Bergenstal RM(2015)Creating and using real-world evidence to answer questions about clinical effectiveness J Innov Health Inf 22 368-335

[13] Meneghini L(2017)Using real-world data for coverage and payment decisions: the ISPOR Real-World Data Task Force report Value Health 10 326-697

[14] Atkin SL(2018)A European, multicentre, retrospective, non-interventional study (EU-TREAT) of the effectiveness of insulin degludec after switching basal insulin in a population with type 1 or type 2 diabetes Diabetes Obes Metab 20 689-58

[15] Gough SC(2017)Real-life experience of patients starting insulin degludec. A multicenter analysis of 1064 subjects from the German/Austrian DPV registry Diabetes Res Clin Pract 29 52-10

[16] Onishi Y(2016)A 1-year, prospective, observational study of Japanese outpatients with type 1 and type 2 diabetes switching from insulin glargine or detemir to insulin degludec in basal-bolus insulin therapy (Kumamoto Insulin Degludec Observational study) J Diabetes Investig 7 3-1055

[17] Iwamoto Y(2017)Improved glycemic control achieved by switching to insulin degludec in insulin-treated patients with type 2 diabetes in a real-world setting: a non-interventional, retrospective cohort study Diabetes Ther 8 1047-2158

[18] Yoo SJ(2018)Clinical outcomes in real-world patients with type 2 diabetes switching from first- to second-generation basal insulin analogues: comparative effectiveness of insulin glargine 300 units/mL and insulin degludec in the DELIVER D+ cohort study Diabetes Obes Metab 20 2148-110

[19] Clauson P(2016)Inpatient hyperglycemia management: the opportunities of a new basal insulin Ital J Med 10 103-undefined

[20] Tamer SC(undefined)undefined undefined undefined undefined-undefined

[11] Rasmussen S(2006)Dispelling myths and removing barriers about insulin in type 2 diabetes Diabetes Educ 32 9S-373

[12] Bergenstal RM(2015)Creating and using real-world evidence to answer questions about clinical effectiveness J Innov Health Inf 22 368-335

[13] Meneghini L(2017)Using real-world data for coverage and payment decisions: the ISPOR Real-World Data Task Force report Value Health 10 326-697

[14] Atkin SL(2018)A European, multicentre, retrospective, non-interventional study (EU-TREAT) of the effectiveness of insulin degludec after switching basal insulin in a population with type 1 or type 2 diabetes Diabetes Obes Metab 20 689-58

[15] Gough SC(2017)Real-life experience of patients starting insulin degludec. A multicenter analysis of 1064 subjects from the German/Austrian DPV registry Diabetes Res Clin Pract 29 52-10

[16] Onishi Y(2016)A 1-year, prospective, observational study of Japanese outpatients with type 1 and type 2 diabetes switching from insulin glargine or detemir to insulin degludec in basal-bolus insulin therapy (Kumamoto Insulin Degludec Observational study) J Diabetes Investig 7 3-1055

[17] Iwamoto Y(2017)Improved glycemic control achieved by switching to insulin degludec in insulin-treated patients with type 2 diabetes in a real-world setting: a non-interventional, retrospective cohort study Diabetes Ther 8 1047-2158

[18] Yoo SJ(2018)Clinical outcomes in real-world patients with type 2 diabetes switching from first- to second-generation basal insulin analogues: comparative effectiveness of insulin glargine 300 units/mL and insulin degludec in the DELIVER D+ cohort study Diabetes Obes Metab 20 2148-110

[19] Clauson P(2016)Inpatient hyperglycemia management: the opportunities of a new basal insulin Ital J Med 10 103-undefined

[20] Tamer SC(undefined)undefined undefined undefined undefined-undefined